Rosiglitazone selectively inhibits KATP channels by acting on the KIR6 subunit

British Journal of Pharmacology

Volumn 167, Issue 1, 2012, Pages 26-36

  Yu, Lei ^a,b   Jin, Xin ^a   Cui, Ningren ^a   Wu, Yang ^a   Shi, Zhenda ^a   Zhu, Daling ^b   Jiang, Chun ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

antagonist; KATP channel; KIR subunit; sulphonylurea receptor; thiazolidinedione

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.X; ISOPROTEIN; ROSIGLITAZONE; SULPHONYLUREA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; IC 50; KINETICS; NUCLEOTIDE SEQUENCE; PATCH CLAMP; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE CELL;

HEK293 CELLS; HUMANS; KATP CHANNELS; POTASSIUM CHANNEL BLOCKERS; PROTEIN SUBUNITS; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 84864696440     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01934.x     Document Type: Article

References (54)

1. Abe M, Takiguchi Y, Ichimaru S, Kaji S, Tsuchiya K, Wada K, (2008). Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method. Eur J Pharmacol 589: 215-219.
2. th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Ashcroft FM, (2006). From molecule to malady. Nature 440: 440-447.
4. Barnett AH, (2009). Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 5: 141-151.
5. Beech DJ, Zhang H, Nakao K, Bolton TB, (1993). K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br J Pharmacol 110: 573-582.
6. + channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. Diabetologia 52: 1112-1121.
7. Coppack SW, Lant AF, McIntosh CS, Rodgers AV, (1990). Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 29: 673-684.
8. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al,. (2000). Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28: 772-780.
9. ATP channel inhibitors, PNU-99963 and PNU-37883A. Br J Pharmacol 139: 122-128.
10. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M, (2001). Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 423: 1-7.
11. ATP channel. Biochem Biophys Res Commun 257: 766-770.
12. Hill A, (1992). Measles, mumps, and rubella vaccination. BMJ 304: 779.
13. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, et al,. (2007). Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113: 211-220.
14. Humphrey SJ, Ludens JH, Perricone SC, Skaletzky LL, Graham BE, Zins GR, (1995). Diuretic activity of N'-disubstituted morpholinoguanidine analogs of U-37883A in rats and dogs. Methods Find Exp Clin Pharmacol 17: 255-266.
15. Irat AM, Aslamaci S, Karasu C, Ari N, (2006). Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones. J Pharm Pharmacol 58: 1647-1653.
16. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, et al,. (2009). PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119: 110-124.
17. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH, (2010). Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. J Am Coll Cardiol 55: 1885-1894.
18. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A, (2002). Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51: 1507-1514.
19. Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, Kintscher U, et al,. (2009). The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes Metab 11: 1060-1067.
20. Knock GA, Mishra SK, Aaronson PI, (1999). Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 368: 103-109.
21. Li H, Chai Q, Gutterman DD, Liu Y, (2003). Elevated glucose impairs cAMP-mediated dilation by reducing Kv channel activity in rat small coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 285: H1213-H1219.
22. ATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia 51: 675-685.
23. Lu YL, Jimbu YM, Chen Y, Zhao JB, Ye TT, Yang H, (2008b). The effects of rosiglitazione on renal artery endothelium in diabetic rats. Exp Clin Endocrinol Diabetes 116: 537-540.
24. Mishra SK, Aaronson PI, (1999). Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes. Eur J Pharmacol 386: 121-125.
25. + channel by decavanadate in guinea-pig ventricular myocytes. Eur J Pharmacol 233: 219-226.
26. ATP channels as molecular sensors of cellular metabolism. Nature 440: 470-476.
27. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
28. + channels. Biophys J 74: 2318-2326.
29. Orie NN, Thomas AM, Perrino BA, Tinker A, Clapp LH, (2009). Ca2+/calcineurin regulation of cloned vascular K ATP channels: crosstalk with the protein kinase A pathway. Br J Pharmacol 157: 554-564.
30. Perricone SC, Humphrey SJ, Skaletzky LL, Graham BE, Zandt RA, Zins GR, (1994). Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs. J Med Chem 37: 3693-3700.
31. Piao H, Cui N, Xu H, Mao J, Rojas A, Wang R, et al,. (2001). Requirement of multiple protein domains and residues for gating K(ATP) channels by intracellular pH. J Biol Chem 276: 36673-36680.
32. Potenza MA, Gagliardi S, De Benedictis L, Zigrino A, Tiravanti E, Colantuono G, et al,. (2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab 297: E685-E694.
33. Quayle JM, Nelson MT, Standen NB, (1997). ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77: 1165-1232.
34. Rojas A, Cui N, Su J, Yang L, Muhumuza JP, Jiang C, (2007). Protein kinase C dependent inhibition of the heteromeric Kir4.1-Kir5.1 channel. Biochim Biophys Acta 1768: 2030-2042.
35. Savoia C, Ebrahimian T, Lemarie CA, Paradis P, Iglarz M, Amiri F, et al,. (2010). Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin Sci (Lond) 118: 583-592.
36. Shi W, Cui N, Shi Y, Zhang X, Yang Y, Jiang C, (2007a). Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am J Physiol Regul Integr Comp Physiol 293: R191-R199.
37. ATP channel activation by beta-adrenergic receptors. Am J Physiol Regul Integr Comp Physiol 293: R1205-R1214.
38. + current of mouse pancreatic beta-cells. Pflugers Arch 431: 625-631.
39. Teramoto N, (2006). Pharmacological Profile of U-37883A, a Channel Blocker of Smooth Muscle-Type ATP-Sensitive K Channels. Cardiovasc Drug Rev 24: 25-32.
40. Torres Tda S, Aguila MB, Mandarim-de-Lacerda CA, (2010). Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring. Pathol Res Pract 206: 642-646.
41. + channels in the absence of the sulphonylurea receptor. Nature 387: 179-183.
42. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G, (1998). Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47: 810-814.
43. Wang CX, Ding X, Noor R, Pegg C, He C, Shuaib A, (2009). Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 29: 1683-1694.
44. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, et al,. (2006). Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317: 37-43.
45. Wang R, Rojas A, Wu J, Piao H, Adams CY, Xu H, et al,. (2005). Determinant role of membrane helices in K ATP channel gating. J Membr Biol 204: 1-10.
46. Wang Y, Lau WB, Gao E, Tao L, Yuan Y, Li R, et al,. (2010). Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 298: E663-E670.
47. Xu H, Yang Z, Cui N, Giwa LR, Abdulkadir L, Patel M, et al,. (2000). Molecular determinants for the distinct pH sensitivity of Kir1.1 and Kir4.1 channels. Am J Physiol Cell Physiol 279: C1464-C1471.
48. ATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery. Biochim Biophys Acta 1778: 88-96.
49. Yang Z, Xu H, Cui N, Qu Z, Chanchevalap S, Shen W, et al,. (2000). Biophysical and molecular mechanisms underlying the modulation of heteromeric Kir4.1-Kir5.1 channels by CO2 and pH. J Gen Physiol 116: 33-45.
50. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, et al,. (2010). Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 38: 86-94.
51. Yu L, Jin X, Yang Y, Cui N, Jiang C, (2011). Rosiglitazone inhibits vascular K(ATP) channels and coronary vasodilation produced by isoproterenol. Br J Pharmacol 164: 2064-2072.
52. Zhu G, Chanchevalap S, Cui N, Jiang C, (1999). Effects of intra- and extracellular acidifications on single channel Kir2.3 currents. J Physiol 516: 699-710.
53. Zhu G, Liu C, Qu Z, Chanchevalap S, Xu H, Jiang C, (2000). CO(2) inhibits specific inward rectifier K(+) channels by decreases in intra- and extracellular pH. J Cell Physiol 183: 53-64.
54. Zinn A, Felson S, Fisher E, Schwartzbard A, (2008). Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 31: 397-403.